Investors on Edge Ahead of Greek Referendum

Related Link: 

With opinion polls suggesting the vote on Greek austerity may be close, many investors are opting to ride out the storm and stick with their holdings of European stocks.

Aetna to Buy Humana for $37 Billion

Related Link: 

Aetna said it would buy Humana for $37 billion, following weeks of frenzied merger talks among large health insurers.

Germany's K+S Rebuffs Potash Takeover

Related Link: 

German salt and fertilizer company K+S AG rejected a takeover approach worth $8.75 billion by rival Potash Corp. of Saskatchewan, saying the proposal undervalued the company.

Airlines' New Normal: More Seats, Fewer Flights

Related Link: 

Using an industry technique known as “upgauging,” airlines increase capacity by adding seats on existing jets and replacing smaller planes with larger ones.

Activism-Defense Specialist Leaving Goldman Sachs

Related Link: 

Activism-defense specialist William Anderson is leaving Goldman Sachs for Evercore Partners, according to people familiar with the matter.

Regulators Warn Banks on Loans to Oil, Gas Producers

Related Link: 

U.S. regulators are sounding the alarm about banks’ exposure to oil and gas producers, a move that could limit their ability to lend to companies battered by a yearlong slump in prices.

Investigators Believe Funds Flowed to Malaysian Leader's Accounts

Related Link: 

Malaysian investigators scrutinizing a government investment fund have traced nearly $700 million of deposits into what they believe are the personal bank accounts of Prime Minister Najib Razak, according to documents from a government probe.

BP to Pay $18.7 Billion to Settle Deepwater Horizon Spill Claims

Related Link: 

BP agreed to pay $18.7 billion over 18 years to settle all federal and state claims arising from 2010’s Deepwater Horizon oil spill, including the biggest pollution penalty in U.S. history.

Vertex's $259,000 Cystic Fibrosis Drug Approved

Related Link: 

Vertex’s cystic-fibrosis drug Orkambi, which treats the most common mutation of the disease, received U.S. regulatory approval on Thursday.

U.S. Regulator Takes Aim at Chrysler

Related Link: 

Regulators are likely to take action before summer’s end against Fiat Chrysler over recall lapses involving older Jeeps tied to rear-end crashes and millions of other vehicles, the U.S. auto-safety chief said.

Syndicate content